Abatacept Trial Concludes With Favorable Results In JM Treatment

Abatacept Trial concludes with favorable results in JM treatment

A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients. The trial was conducted at the Cure JM Center of Excellence at George Washington University, and preliminary results were presented at the Global Conference on Myositis.

Abatacept was generally well tolerated with minimal side effects, and the preliminary data suggest that abatacept may be beneficial in the treatment of hard-to-treat JM patients. Importantly, patients using abatacept improved at the same time prednisone dosage was reduced.  

The ten JM patients enrolled in the pilot study were between the ages of seven and 17, and all had moderate disease activity and moderately decreased functional disability. Five of the ten patients met the definition of improvement at week 12 of the trial, and nine met the definition by week 24. At week 24, three of the ten patients saw major improvement, four saw moderate improvement, and two saw minimal improvement when using Core Set Measures against a scale utilized by the International Myositis Assessment and Clinical Studies Group (IMACS).  

When assessing improvements in Core Set Measures against a similar scale used by the Pediatric Rheumatology International Trials Organization (PRINTO), seven of the nine improved patients saw major improvements in their scores. One patient was discontinued from the trial due to worsening interstitial lung disease.

“These results are preliminary but are certainly very encouraging,” said Dr. Rodolfo Curiel, the trial’s principal investigator. 

“We have much more data to assess before we publish the results, yet the pilot study showed that patients with refractory JDM treated with abatacept resulted in lower disease activity and clinically significant responses in the majority of patients.” Dr. Curiel is the Director of the Cure JM Center of Excellence at George Washington University.

Traveling with JM

Planning a trip or vacation can be challenging, especially when you have a child with juvenile myositis. With spring break and summer break just around the corner, the pressure might be even greater. However, at Cure JM, we want to help ensure that you and your child can enjoy all the delights of a vacation with minimal stress.

A Grandparent Spotlight – Anita

Cure JM recently had the pleasure of interviewing a remarkable individual who hails from Canton, Ohio, and brings a wealth of experience and love to her family. With a vibrant history spanning over five decades of marriage, three daughters, and a rich tapestry of grandchildren and great-grandchildren, Anita Mottice’s journey is as inspiring as it is heartwarming. As a retired nurse and devoted wife, Anita shares her profound connection with her family, particularly her grandchild Sydney, who has been diagnosed with Juvenile Myositis (JM).

GCOM 2024 Round Up

GCOM — Day 1 Opening with Influence & Innovation Today was a most impressive day for Cure JM at the Global Conference for Myositis.  The

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.